Group 1 - The cosmetics sector increased by 0.56% on September 1, with Lafang Jiahua leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] - Lafang Jiahua's stock price rose by 9.99% to 26.97, with a trading volume of 114,000 shares and a transaction value of 300 million yuan [1] Group 2 - The cosmetics sector saw a net inflow of 15.558 million yuan from institutional investors, while retail investors contributed a net inflow of 45.296 million yuan [2] - Major stocks in the sector experienced varied capital flows, with Lafang Jiahua having a net inflow of 75.247 million yuan from institutional investors [3] - Other companies like Jiahen Jiahua and Huaye Fragrance also saw significant net inflows, while stocks like Marubi Biological and Shanghai Jahwa experienced net outflows from institutional and retail investors [3]

Industry Overview - The beauty industry is witnessing significant developments, including financial reports from various companies and the successful registration of new raw materials like Ursolic Acid [1] - Major brands are launching new products and entering new markets, indicating a dynamic and evolving landscape [1] Company Performance - Up Beauty reported a record revenue of 4.108 billion yuan for the first half of 2025, a year-on-year increase of 17.3%, with a net profit of 556 million yuan, up 34.7% [2] - Giant Biological achieved a revenue of 3.113 billion yuan in the first half of 2025, reflecting a 22.5% year-on-year growth, with a net profit of 1.182 billion yuan, up 20.6% [21] - Huaxi Biological reported a revenue of 2.261 billion yuan, with net profit figures showing no growth, but signs of strategic adjustments beginning to take effect [22] - Marubi Biological's revenue for the first half of 2025 reached 1.769 billion yuan, a 30.83% increase year-on-year, with a net profit of 186 million yuan, up 5.21% [23] New Product Developments - Up Beauty is preparing to launch a new makeup brand called "Dan Cai" in collaboration with a renowned makeup artist [2] - COSMAX announced breakthroughs in anti-aging and whitening products, including a new NAD-based anti-aging cosmetic and a new whitening powder [3] - LV Cosmetics has begun global pre-sales, indicating a strong push into the market [15] Executive Changes - Proya appointed new executives, including Xue Xia as the board secretary and Guo Xiao as the Chief Marketing Officer, both bringing extensive experience in the consumer sector [4] - Givaudan announced a leadership change, with Gilles Andrier stepping down as CEO in March 2026, to be succeeded by Christian Stammkoetter [5] Market Trends - The beauty and skincare market saw sales of 235.23 billion yuan in the first half of 2025, a 10.1% year-on-year increase, with anti-aging products showing a significant growth of 30.3% [24] - The introduction of innovative products and strategic partnerships, such as COSMAX's collaboration with Korea University for climate-proof cosmetics, reflects the industry's adaptability to changing consumer needs [15]

Core Insights - The beauty industry in China is experiencing a significant performance divergence among leading companies, with a notable emphasis on quality improvement amidst a deep industry adjustment [1][2]. Group 1: Industry Performance - In the first half of 2025, retail sales of cosmetics in China increased by 2.9% year-on-year, with domestic brands capturing over 55% market share [2]. - Exports of cosmetics surged by 12% to 25.8 billion yuan, indicating strong overseas growth potential [2]. Group 2: Leading Companies - Leading companies like Proya, Mao Geping, and Shangmei continue to excel, while others like Huaxi Biological and Fulejia are lagging behind [2]. - Proya reported revenue of 5.362 billion yuan, a 7.21% increase, and a net profit of 799 million yuan, up 13.8% [4]. - Mao Geping achieved a revenue of 2.588 billion yuan, with a remarkable growth rate of 31.3%, and a net profit of 670 million yuan, reflecting a 36.1% increase [5]. - Shangmei's revenue reached 4.108 billion yuan, growing by 17.3%, with a net profit of 556 million yuan, up 34.7% [5]. - Juzhi Biological reported revenue of 3.113 billion yuan, a 22.5% increase, and a net profit of 1.182 billion yuan, up 20.2% [5]. Group 3: Underperforming Companies - Huaxi Biological reported a significant decline, with revenue dropping nearly 19.57% to 2.261 billion yuan and net profit falling 35.38% to 221 million yuan [6]. - Fulejia's revenue decreased by 8.15% to 863 million yuan, with a net profit decline of 32.54% to 230 million yuan, largely due to increased marketing expenses [9][11]. Group 4: Second-Tier Companies - Second-tier companies like Shanghai Jahwa, Marubi, and Shuiyang are showing improved performance [13]. - Shanghai Jahwa's revenue was 3.478 billion yuan, up 4.8%, with a net profit of 270 million yuan, increasing by 11.7% [14]. - Marubi achieved revenue of 1.769 billion yuan, a 30.83% increase, but net profit growth was only 5.21% [14]. - Shuiyang reported revenue of 2.5 billion yuan, a 9.02% increase, and a net profit of 123 million yuan, up 16.54% [14].

Core Viewpoint - The beauty industry in China is experiencing a significant performance divergence among leading companies, with a notable increase in quality, as evidenced by the half-year reports of domestic beauty brands [2]. Group 1: Leading Companies Performance - Leading beauty companies such as Proya, Mao Geping, and Shangmei continue to outperform, while Huaxi Biological and Fulejia are lagging behind [2][4]. - Proya reported a revenue of 5.362 billion yuan, a year-on-year increase of 7.21%, and a net profit of 799 million yuan, up 13.8%. However, its main brand experienced a slight revenue decline of 0.08% [5][6]. - Mao Geping, known as the "first stock of high-end domestic beauty," achieved a revenue of 2.588 billion yuan, with a net profit of 670 million yuan, both showing over 30% growth. The gross margin reached 84.2% [6]. - Shangmei's revenue was 4.108 billion yuan, growing 17.3%, with a net profit of 556 million yuan, up 34.7%. The "newpage" brand saw a revenue increase of 146.5% [6][7]. - Juzhi Biological reported a revenue of 3.113 billion yuan, a 22.5% increase, and a net profit of 1.182 billion yuan, up 20.2%, although growth rates have slowed compared to the previous year [7]. Group 2: Underperforming Companies - Huaxi Biological, referred to as the "first stock of hyaluronic acid," reported a revenue decline of 19.57% to 2.261 billion yuan and a net profit drop of 35.38% to 221 million yuan, marking its worst interim report since listing [9]. - The decline in Huaxi's revenue is attributed to a significant drop in its functional skincare business, which saw a 31.62% year-on-year decrease in 2024 [9]. - Fulejia's revenue was 863 million yuan, down 8.15%, with a net profit of 230 million yuan, a decrease of 32.54%. The company faced a substantial increase in sales expenses, which rose by 39.56% [11][12]. Group 3: Second-Tier Companies - Second-tier beauty companies such as Shanghai Jahwa, Marubi, and Shuiyang are showing improved performance [13][14]. - Shanghai Jahwa achieved a revenue of 3.478 billion yuan, a 4.75% increase, and a net profit of 266 million yuan, up 11.66%, attributed to online channel growth [15]. - Marubi reported a revenue of 1.769 billion yuan, a 30.83% increase, but its net profit only grew by 5.21%, indicating a potential profitability challenge [15][16]. - Shuiyang's revenue reached 2.5 billion yuan, a 9.02% increase, with a net profit of 123 million yuan, up 16.54%. The company is transitioning to a global high-end beauty brand management model [16].

Investment Rating - The investment rating for the company is "Accumulate" with a target price of 56.57 CNY [4][10]. Core Insights - The company focuses on big product lines and streamlining its main brand SKU strategy to drive continuous improvement in gross margin. However, the significant decline in offline channels in 1H25 has impacted main brand growth. There are expectations for new products to expand the consumer base and improve operational efficiency on platforms like Douyin [2][10]. - In 1H25, the company reported total revenue of 2.372 billion CNY, a year-on-year decline of 15.43%, and a net profit attributable to the parent company of 247 million CNY, down 49.0% year-on-year. The gross margin improved to 76.0%, up 3.42 percentage points, attributed to a focus on big products and reduced promotions [10][11]. - The company has adjusted its EPS forecasts for 2025 and 2026 to 1.12 CNY and 1.49 CNY, respectively, reflecting the impact of short-term offline channel adjustments and product line streamlining [10][11]. Financial Summary - For 2023A, the total revenue is projected at 5.522 billion CNY, with a year-on-year growth of 10.1%. The net profit attributable to the parent company is expected to be 757 million CNY, down 28.0% [3][11]. - The company’s gross margin is expected to improve to 75.3% in 2025E, with a net profit margin of 8.6% [11]. - The company’s total assets are projected to reach 8.456 billion CNY by 2025E, with total liabilities of 1.936 billion CNY [11]. Market Performance - The stock has a 52-week price range of 39.34 CNY to 70.30 CNY, with a total market capitalization of 19.871 billion CNY [5][10]. - The stock has shown an absolute increase of 14% over the past 12 months, although it has underperformed relative to the index by 41% [9][10].

Investment Rating - The investment rating for the company is "Buy" [6][18] Core Insights - The company reported a steady growth in revenue and net profit for the first half of 2025, with year-on-year increases of 23% and 20% respectively, indicating strong performance and effective cost control [2][10] - The sales expense ratio has decreased year-on-year, highlighting improved operational efficiency [10] - The company is focusing on the performance of key products and new launches, which are expected to drive future growth [10] Financial Summary - Total revenue for 2023 is projected at 3,524 million RMB, with a growth forecast to 5,539 million RMB in 2024, and reaching 10,402 million RMB by 2027, reflecting a compound annual growth rate (CAGR) of 22.4% [4][12] - Net profit is expected to grow from 1,452 million RMB in 2023 to 3,795 million RMB by 2027, with a CAGR of 23.4% [4][12] - The company maintains a high gross profit margin, projected at 81.7% for the first half of 2025, despite a slight year-on-year decrease [10] Revenue Breakdown - For the first half of 2025, revenue from various channels showed significant growth: DTC online direct sales increased by 13%, e-commerce platform direct sales surged by 134%, and offline direct sales rose by 12% [10] - The main brand, "可复美," launched upgraded products that performed well in the market, indicating strong brand momentum [10] Product Development - The company continues to innovate with new product launches, including an upgraded collagen stick and a new skincare series, which are expected to enhance market presence and meet consumer demands [10]

Group 1 - The cosmetics sector increased by 1.05% on August 29, with Jiaheng Jiahua leading the gains [1] - The Shanghai Composite Index closed at 3857.93, up 0.37%, while the Shenzhen Component Index closed at 12696.15, up 0.99% [1] - Jiaheng Jiahua's stock price rose by 20.01% to 31.85, with a trading volume of 138,900 shares and a transaction value of 434 million yuan [1] Group 2 - The cosmetics sector saw a net inflow of 10.35 million yuan from institutional investors, while retail investors contributed a net inflow of 88.15 million yuan [2] - Major stocks in the sector experienced varied capital flows, with Jiaheng Jiahua having a net inflow of 76.21 million yuan from institutional investors [3] - Shanghai Jiahua had a net inflow of 35.86 million yuan from institutional investors, but a net outflow of 51.01 million yuan from retail investors [3]

Group 1: AI Industry Insights - The report highlights the release of the "Artificial Intelligence+" action plan by the State Council, which aims to strengthen foundational support capabilities in AI, including innovation in AI chips and software ecosystem development [3] - The action plan is expected to provide long-term institutional guarantees for the development of the AI industry, addressing current bottlenecks such as insufficient computing power and low-quality data supply [3] - Companies to watch include those involved in AI technology and applications, such as Kingdee International, Meituan, and various players in AI education and healthcare [3] Group 2: Economic and Market Outlook - The "14th Five-Year Plan" emphasizes the need for a unified market to break local protectionism and promote efficient resource allocation [4] - The plan also aims to support consumer spending and upgrade consumption structures, indicating a shift in fiscal spending towards improving livelihoods [4] - The capital market reform during this period is expected to transition from policy-driven to institution-driven, promoting high-quality development of the capital market [4] Group 3: Aerospace Industry Developments - China's commercial aircraft market share exceeds 20%, with the C919 aircraft production capacity expanding, potentially breaking the Airbus and Boeing duopoly [4] - The demand for commercial engines in China is projected to exceed $600 billion over the next 20 years, with an average annual demand of over 200 billion RMB [4] - The report indicates that the domestic aerospace industry is likely to experience significant growth due to the focus on local market development and self-sufficiency [4] Group 4: Semiconductor Sector Performance - Changdian Technology reported a revenue of 18.605 billion RMB for the first half of 2025, reflecting a year-on-year growth of 20.14%, driven by increased domestic orders and market demand recovery [8][34] - The company's net profit decreased by 23.98% due to ongoing construction of new factories and rising financial costs, but gross margin improved from 12.6% to 14.3% [34][38] - The semiconductor industry is experiencing a recovery, with global sales expected to continue growing, providing opportunities for companies in this sector [36] Group 5: Consumer Electronics and Home Appliances - Wanhe Electric reported a revenue of 4.08 billion RMB in the first half of 2025, with overseas revenue growing by 26.5% while domestic revenue declined by 4.4% [16] - The company is focusing on digital transformation and cost optimization to enhance its competitiveness in both domestic and international markets [16] - The report anticipates steady growth in the home appliance sector, driven by innovations and expansion into overseas markets [16] Group 6: Automotive and New Energy Sectors - Tuhu-W reported a revenue of 7.877 billion RMB in the first half of 2025, with a year-on-year growth of 10.54%, driven by expansion into lower-tier cities [17] - The company is enhancing its supply chain and logistics efficiency, which has positively impacted its operational performance [17] - The new energy vehicle segment is emerging as a significant growth driver, with a notable increase in transaction users on the platform [17]

New Consumption - The company achieved total operating revenue of 1.769 billion yuan in H1 2025, a year-on-year increase of 30.83% [2][8] - The total profit reached 241 million yuan, up 7.17% year-on-year, while the net profit attributable to shareholders was 186 million yuan, reflecting a growth of 5.21% [2][10] - The main brand, Marubi, maintained its position as the "No. 1 domestic brand in eye care" and the PL brand won the "Most Influential Makeup and Fragrance Brand" award [2][9] Machinery/Building Materials - The company reported operating revenue of 161 million yuan in H1 2025, a significant increase of 51.66% year-on-year, with a net profit of 23 million yuan, up 199.23% [12][15] - The balance machine business showed steady growth, while automation equipment and software information systems contributed significantly to performance [13][15] - The company is recognized as a leader in domestic balance machines, with new orders expected to increase as the company expands into high-end equipment manufacturing markets [15] Transportation - The company achieved approximately 766 million yuan in revenue in H1 2025, a decrease of 8.57% year-on-year, while the net profit was approximately 532 million yuan, an increase of 20.51% [16][17] - The main business of highways remains stable, with a significant increase in net profit in Q2 2025 due to the recovery of previously provisioned losses [16][17] - The company plans to distribute a cash dividend of 0.15 yuan per share, indicating a commitment to shareholder returns [16][18] North Exchange - The company reported revenue of 237 million yuan in H1 2025, a year-on-year increase of 7%, with a net profit of 52.68 million yuan, up 14% [20][21] - The domestic revenue grew by 31%, while overseas revenue faced challenges [21] - The company is actively developing new products in nuclear power and data center sectors, which are expected to drive future growth [21][22] Hydraulic Industry - The company achieved revenue of 344 million yuan in H1 2025, a year-on-year increase of 13%, with a net profit of 67.32 million yuan, up 40% [31][32] - The growth was driven by strong demand for dump truck cylinders and oil-gas springs, with significant improvements in gross margins [32][33] - The company is expanding into new fields such as autonomous driving and industrial robotics, indicating a strategic shift towards innovative applications [34][35]

Investment Rating - The report assigns an "Outperform" rating for Marubi Biotechnology, expecting the stock's total return over the next 12-18 months to exceed the return of its relevant broad market benchmark [20]. Core Insights - Marubi achieved operating revenue of 1.769 billion yuan in the first half of 2025, representing a year-on-year increase of 30.83%, driven by brand innovation, channel expansion, and operational efficiency improvements [2][8]. - The company's online channels generated 1.571 billion yuan in revenue during the first half of 2025, up 37.85% year-on-year, while offline channels saw a decline of 7.07% to 197 million yuan [2][8]. - Marubi's gross margin for the first half of 2025 was 74.6%, slightly down by 8 basis points year-on-year, attributed to optimization in product and sales structures [2][8]. Revenue and Growth - In Q2 2025, Marubi's revenue reached 923 million yuan, marking a 33.5% year-on-year growth [2][8]. - The Marubi brand generated 1.25 billion yuan in revenue in the first half of 2025, up 34.36% year-on-year, accounting for 70.72% of total revenue [2][8]. - The PASSIONAL LOVER brand achieved 516 million yuan in revenue, a 23.87% increase year-on-year, representing 29.22% of total revenue [2][8]. Cost and Profitability - Sales expenses in the first half of 2025 were 1 billion yuan, up 39.31% year-on-year, leading to a sales expense ratio of 56.5%, an increase of 3.4 percentage points [3][9]. - The net profit attributable to the parent company for the first half of 2025 was 186 million yuan, a 5.21% increase year-on-year, with a net profit margin of 10.5%, down 2.6 percentage points [3][9]. Product Development and Market Position - Marubi expanded its product range, particularly in eye care and anti-aging, with the Little Red Pen Eye Cream achieving a 150% year-on-year sales growth in the first half of 2025 [4][10]. - The Little Golden Needle Serum and other products maintained strong sales performance, with the Little Golden Needle Super Mask reaching a market share of 4.23% on TikTok [4][10]. Marketing and Sales Strategy - The company adopted an eight-account matrix operation model for self-broadcasting, achieving a penetration rate of 82% [5][11]. - Marubi's self-broadcasting business saw a 60% year-on-year increase in Q1 2025 and a 10% increase in Q2 2025 [5][11].